CA2693057A1 - Oral formulations for picoplatin - Google Patents

Oral formulations for picoplatin Download PDF

Info

Publication number
CA2693057A1
CA2693057A1 CA 2693057 CA2693057A CA2693057A1 CA 2693057 A1 CA2693057 A1 CA 2693057A1 CA 2693057 CA2693057 CA 2693057 CA 2693057 A CA2693057 A CA 2693057A CA 2693057 A1 CA2693057 A1 CA 2693057A1
Authority
CA
Canada
Prior art keywords
picoplatin
formulation
cancer
oil
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2693057
Other languages
English (en)
French (fr)
Inventor
Andrew Xian Chen
Cheni Kwok
Christopher A. Procyshyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2693057A1 publication Critical patent/CA2693057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2693057 2007-07-16 2008-07-16 Oral formulations for picoplatin Abandoned CA2693057A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95003307P 2007-07-16 2007-07-16
US60/950,033 2007-07-16
US4396208P 2008-04-10 2008-04-10
US61/043,962 2008-04-10
PCT/US2008/008669 WO2009011861A1 (en) 2007-07-16 2008-07-16 Oral formulations for picoplatin

Publications (1)

Publication Number Publication Date
CA2693057A1 true CA2693057A1 (en) 2009-01-22

Family

ID=40259929

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2693057 Abandoned CA2693057A1 (en) 2007-07-16 2008-07-16 Oral formulations for picoplatin

Country Status (7)

Country Link
US (1) US20100310661A1 (enExample)
EP (1) EP2178893A4 (enExample)
JP (1) JP2010533714A (enExample)
CN (1) CN101809024A (enExample)
CA (1) CA2693057A1 (enExample)
TW (1) TW200920347A (enExample)
WO (1) WO2009011861A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) * 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20120148661A1 (en) * 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
MX348668B (es) * 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Nanopartículas de oxaliplatin y método para prepararlas.
AU2011260615B2 (en) * 2010-06-02 2016-11-17 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
EP2773323A4 (en) 2011-10-31 2015-04-22 Merck Sharp & Dohme NANO-SUSPENSION METHOD
CN104427977B (zh) 2012-05-10 2018-02-02 佩因拉佛姆有限公司 局部麻醉剂的储库制剂及其制备方法
KR101612257B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
WO2017018635A1 (ko) * 2015-07-30 2017-02-02 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
KR101612260B1 (ko) 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
GB2541387A (en) * 2015-08-14 2017-02-22 Res Center Pharmaceutical Eng Gmbh Self-emulsifying Nanosuspensions as Drug Delivery Systems (SENDDS)
WO2017096530A1 (zh) * 2015-12-08 2017-06-15 广州中科蓝华生物科技有限公司 癸氧喹酯固体分散体、其制备方法和用途
EP3626271A4 (en) * 2017-05-18 2021-02-24 Kewpie Corporation SELF-SYSTEMULABLE COMPOSITION, MANUFACTURING METHODS FOR IT, NANOEMULSION AND MANUFACTURING METHODS FOR IT
CN108066771A (zh) * 2017-12-15 2018-05-25 北京思如诺科技有限公司 一种具有高载药量环境响应型抗肿瘤纳米药物、载体以及制备方法
PL247245B1 (pl) * 2019-01-31 2025-06-02 Gdanski Univ Medyczny Samoemulgująca kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym
US20240252464A1 (en) * 2022-07-06 2024-08-01 Avantsar Sdn Bhd A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound
CN119699569B (zh) * 2024-12-23 2025-10-17 晨光生物科技集团股份有限公司 一种叶黄素酯油悬液及其制备方法与应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623782A (en) * 1899-04-25 Filtering-intake
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB2060615B (en) * 1979-08-23 1983-06-22 Johnson Matthey Co Ltd Platinum-amine complexes
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
GR75317B (enExample) * 1980-09-03 1984-07-13 Johnson Matthey Plc
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
KR900003457B1 (ko) * 1986-12-18 1990-05-19 시오노기세이야꾸 가부시끼가이샤 암민-지환식아민-백금 착화합물 및 항종양제
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5244991A (en) * 1991-10-15 1993-09-14 Phillips Petroleum Company Olefin polymerization process
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
JP3633932B2 (ja) * 1992-04-01 2005-03-30 ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
US5798589A (en) * 1995-09-13 1998-08-25 Zexel Corporation Brushless motor having lubrication system for upper and lower bearings
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
DK1165576T3 (da) * 1999-04-13 2006-03-27 Anormed Inc Fremgangsmåde til fremstilling af amin-platin-komplekser
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
DE60032517T2 (de) * 2000-02-16 2007-10-04 Astellas Pharma Inc. Heilmittel gegen durch endothelin verursachte erkrankungen
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20020110601A1 (en) * 2000-03-31 2002-08-15 Roman Perez-Soler Antineoplastic platinum therapeutic method and composition
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU2001277099B2 (en) * 2000-07-24 2006-08-31 Pharmacia & Upjohn Company Llc Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
AU2001277711A1 (en) * 2000-08-11 2002-02-25 Sumitomo Pharmaceuticals Co. Ltd. Remedies for cisplatin-tolerant cancer
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
CA2326004A1 (en) * 2000-11-02 2002-05-02 Richard E. Jones Methods for treating cellular proliferative disorders
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6673370B2 (en) * 2001-05-15 2004-01-06 Biomedicines, Inc. Oxidized collagen formulations for use with non-compatible pharmaceutical agents
PT1416917E (pt) * 2001-08-06 2007-08-16 Astrazeneca Ab ''dispersão aquosa compreendendo nanopartículas estáveis de um triglicérido de cadeia média (mct) activo insolúvel em água e um do tipo excipiente''
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
AU2003220022A1 (en) * 2002-03-01 2003-09-16 Trustees Of Dartmouth College Compositions and methods for preventing sporadic neoplasia in colon
ES2283756T3 (es) * 2002-03-01 2007-11-01 Novagali Pharma Sa Sistemas autoemulsionantes de administracion de farmaco para taxoides.
US20040010553A1 (en) * 2002-07-15 2004-01-15 International Business Machines Corporation Peer to peer location based services
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
ATE389650T1 (de) * 2003-04-30 2008-04-15 Merck Patent Gmbh Chromenonderivate
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2027853A3 (en) * 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US7807662B2 (en) * 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
WO2008150506A1 (en) * 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
ATE530169T1 (de) * 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer

Also Published As

Publication number Publication date
JP2010533714A (ja) 2010-10-28
US20100310661A1 (en) 2010-12-09
TW200920347A (en) 2009-05-16
WO2009011861A1 (en) 2009-01-22
EP2178893A4 (en) 2012-09-19
EP2178893A1 (en) 2010-04-28
CN101809024A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
US20100310661A1 (en) Oral formulations for picoplatin
Couillaud et al. State of the art of pharmaceutical solid forms: from crystal property issues to nanocrystals formulation
Bhalekar et al. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir
Mukherjee et al. Solid lipid nanoparticles: a modern formulation approach in drug delivery system
ES2952025T3 (es) Una formulación de rapamicina inhalable para tratar condiciones relacionadas con la edad
Makwana et al. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach
KR100923172B1 (ko) 신규 약물 제제
JP2021008521A (ja) アビラテロン酢酸エステル製剤
US20110207804A1 (en) Compositions for the treatment of neoplastic diseases
JP2018510221A (ja) Ｐａｒｐ阻害剤固形医薬剤型及びその使用
JP2010533714A5 (enExample)
WO2019155416A2 (en) A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
Srivalli et al. Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption
Schultz et al. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate: Schultz, Joyce, Thomas and Prestidge
Maji et al. Benchmarking of pH-responsive mixed micelles for repurposed breast cancer therapy of ibrutinib with molecular modeling and pharmacokinetic insights
WO2011034394A2 (ko) 옥살리플라틴의 나노 입자 및 이를 제조하는 방법
Bunjes et al. Manufacture, characterization, and applications of solid lipid nanoparticles as drug delivery systems
US20120148661A1 (en) High bioavailability oral picoplatin anti-cancer therapy
KR101180181B1 (ko) 나노 입자 및 그의 제조 방법
Gao et al. In-vitro evaluation of paclitaxel-loaded MPEG–PLGA nanoparticles on laryngeal cancer cells
MX2008001970A (es) Formulaciones para 7-(t-butoxi)iminometil camptotecin.
CA2612288A1 (en) Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
HK1147497A (en) Oral formulations for picoplatin
Juan-Juan et al. Improved stability and oral bioavailability of Ganneng dropping pills following transforming lignans of herpetospermum caudigerum into nanosuspensions
Thomas et al. Formulation and evaluation of anti-arthritis drug loaded stealth liposomes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140716